Self-disassembling nanoparticles as oral nanotherapeutics targeting intestinal microenvironment.

Area of Science:

• Biomaterials Science
• Microbiology
• Nanomedicine

Background:

• Pyomelanin-producing microbes inspire novel biomaterial development.
• Inflammatory bowel disease (IBD) requires innovative therapeutic strategies.

Purpose of the Study:

• To synthesize and characterize pyomelanin nanoparticles (PMNPs) for potential biomedical applications.
• To evaluate the therapeutic efficacy of PMNPs in an inflammatory bowel disease model.

Main Methods:

• Synthesis of PMNPs from homogentisic acid- γ-lactone via auto-oxidation.
• Assessment of PMNP physicochemical properties, including reactive oxygen species scavenging and self-disassembly.
• In vivo evaluation of orally administered PMNPs in an IBD model, analyzing effects on gut microbiota, inflammation, and clinical symptoms.

Main Results:

• PMNPs demonstrated reactive oxygen species scavenging and microenvironment-responsive self-disassembly.
• Oral PMNP administration effectively reduced reactive oxygen species, exerted anti-inflammatory effects, and restored gut microbiota composition in an IBD model.
• PMNPs showed superior therapeutic efficacy compared to conventional nanoparticles and 5-aminosalicylic acid, alleviating clinical symptoms and intestinal inflammation.

Conclusions:

• Pyomelanin nanoparticles (PMNPs) exhibit significant therapeutic potential for treating inflammatory bowel disease.
• PMNPs demonstrate a promising approach for modulating gut inflammation and microbiota.
• The findings suggest broader biomedical applications for PMNPs beyond IBD treatment.